TheraRadar
← Back
Data updated: Jun 28, 2026

SUNSHINE

Generics
DermatologyInfectious DiseaseRespiratory Execution: Needs Improvement

SUNSHINE is a generic drug manufacturer focused on Dermatology, Infectious Disease, Respiratory.

2018
Since
25
Drugs
-
Trials
1
New Drugs (2yr)
Modality:

SUNSHINE at a Glance

  • Growing R&D activity with 20 trials in last 2 years
  • Fast trial execution (17 months median completion)

SUNSHINE's Key Drugs

SUNSHINE's core commercial portfolio centers on LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, spanning Dermatology and Infectious Disease — its most strategically important drugs approved in the last 15 years.

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
Metabolic

Type 2 Diabetes

DPP-4 Approved 2021

SUNSHINE's Recent FDA Approvals

SUNSHINE secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

DULOXETINE HYDROCHLORIDE NDA
2026-02-27
duloxetine hydrochloride

SUNSHINE's Therapeutic Areas

SUNSHINE's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 24%
3 drugs Phase 3: 6 Phase 2: 1 Phase 1: 4
Infectious Disease 23%
3 drugs Phase 3: 1 Phase 2: 5 Phase 1: 15
Respiratory 22%
3 drugs Phase 3: 3 Phase 2: 4 Phase 1: 6
Oncology 19%
0 drugs Phase 3: 3 Phase 2: 4 Phase 1: 18
Cardiovascular 12%
4 drugs

SUNSHINE Pipeline Snapshot

SUNSHINE has 70 active clinical programs from ClinicalTrials.gov — 13 Phase 3, 14 Phase 2 and 43 Phase 1.

13
Phase 3
14
Phase 2
43
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • LINAGLIPTIN AND METFORMIN HYDROCHLORIDE leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Dermatology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 4/11 completed
  • • Speed: 17 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges